NCT02522754View on ClinicalTrials.gov

Development of an Intranasal Proteosome Influenza Vaccine

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

January 31, 2002

Primary Completion Date

January 31, 2004

Study Completion Date

January 31, 2004

Conditions
Influenza
Interventions
BIOLOGICAL

Placebo Protesomal Vaccine

Intranasal vaccine Protesomal Vaccine

BIOLOGICAL

Experimental: Protesomal Vaccine 1 x 30 µg

Experimental: Protesomal Vaccine 1 x 30 µg

BIOLOGICAL

Experimental: Protesomal Vaccine 2 x 30 µg

Experimental: Protesomal Vaccine 2 x 30 µg

BIOLOGICAL

Experimental: Protesomal Vaccine 2 x 15 µg

Experimental: Protesomal Vaccine 2 x 15 µg

Sponsors

Lead Sponsor

Hvivo

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Hvivo

INDUSTRY